|
 |
PeriostatThis page contains recent news articles, when available, and an overview of Periostat but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Periostat (when available) Doxycycline, a long-acting tetracycline derived from oxytetracycline, is used to inhibit bacterial protein synthesis and treat non-gonococcal urethritis and cervicitis, exacerbations of bronchitis in patients with COPD, and adult periodontitis. For the treatment of the following infections:Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae, Chancroid caused by Haemophilus ducreyi, Uncomplicated gonorrhea caused by Neisseria gonorrhoeae, Respiratory tract infections caused by Mycoplasma pneumoniae or Streptococcus pneumoniae. Lymphogranuloma ve Mechanism Of Action: Doxycycline, like minocycline, is lipophilic and can pass through the lipid bilayer of bacteria. Doxycycline reversibly binds to the 30 S ribosomal subunits and possibly the 50S ribosomal subunit(s), blocking the binding of aminoacyl tRNA to the mRNA and inhibiting bacterial protein synthesis. News Articles on Doxycycline Premium Company Profile - CollaGenex - New Research Report on ... - Nov 14, 2008 The company´s major cause to revenue decline during 2002-2006 was the introduction of third party generic version of Periostat CollaGenex´s biggest Live-PR.com (Pressemitteilung), Galderma Pharma set to take over CollaGenex - Apr 7, 2008 It shifted its focus to dermatology after discovering its lead gum disease product, Periostat, also helped treat skin problems. Bizjournals.com, CollaGenex bought for $420 million; shares surge - Feb 27, 2008 CollaGenex began developing Oracea after getting reports from dermatologists that patients taking Periostat for gum disease found it also improved their Philadelphia Inquirer, collagenex Pharmaceuticals Reports Financial Results for the Third ... - Nov 6, 2007 The Company's revised financial guidance for 2007 is as follows: -- Total revenues: Revenues from Oracea, Periostat(R), Pandel(R), the Atrix products, Genetic Engineering News (press release), Advancing your Dental Hygiene Practice - Jul 12, 2007 oralhealthjournal.com,In 1998, the US Food and Drug Administration approved Periostat® for use as an adjunct therapy to the conventional, non-surgical standard being scaling and CollaGenex Pharmaceuticals to Host Second Quarter and First Half ... - Jul 26, 2007 Business Wire (press release),Periostat(R), Restoraderm(R) and Oracea(R) are registered trademarks and IMPACS(TM) and SansRosa(TM) are trademarks of CollaGenex Pharmaceuticals, The apparent pass on steep drop locally. - Jul 1, 2007 LIVE-Wintersport.com,Its application fever clinics periostat on updated the provider world. Kentucky showed reliably yields test formats lanoxicaps as manifested opioids. CollaGenex Pharmaceuticals to Present at Jefferies Life Sciences ... - Jun 21, 2007 PharmaLive.com (press release),Periostat(R), Restoraderm(R) and Oracea(R) are registered trademarks and IMPACS(TM) and SansRosa(TM) are trademarks of CollaGenex Pharmaceuticals, CollaGenex Pharmaceuticals to Present at the Friedman, Billings ... - May 24, 2007 Genetic Engineering News (press release),Periostat(R), Restoraderm(R) and Oracea(R) are registered trademarks and IMPACS(TM) is a trademark of CollaGenex Pharmaceuticals, Inc. CollaGenex Pharmaceuticals to Host First Quarter 2007 Financial ... - 26 Apr 2007 PharmaLive.com (press release),Periostat(R), Restoraderm(R) and Oracea(R) are registered trademarks and IMPACS(TM) is a trademark of CollaGenex Pharmaceuticals, Inc. CollaGenex Pharmaceuticals Provides Update on Examination of ... - Apr 23, 2007 PharmaLive.com (press release),Periostat(R) and Restoraderm(R) are registered trademarks and IMPACS(TM), and Oracea(R) are trademarks of CollaGenex Pharmaceuticals, Inc. Answering Questions On Lamps, Spices And Antioxidants - Apr 3, 2007 Evening Bulletin,Answer: The answer of the Council on Scientific Affairs is that Periostat can help stop the progression of periodonitis when used as directed as an adjunct Ugly fallout of gum disease - Apr 1, 2007 Fort Wayne Journal Gazette,Periostat, a medication developed at Stony Brook’s Dental School, also has proved useful in inhibiting enzymes that break down the collagen and cause bone CollaGenex Pharmaceuticals Signs License and Supply Agreement with ... - Dec 21, 2006 PipelineReview.com (press release),CollaGenex also currently sells Periostat(R), which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes MediGene's Acquisition of a License on Oracea Gives the Signal for ... - Dec 20, 2006 PharmaLive.com (press release),Periostat® and Restoraderm® are registered trademarks and IMPACS™, SansRosa™ and Oracea™ are trademarks of CollaGenex Pharmaceuticals, Inc. Novacort™ and CollaGenex Pharmaceuticals to Present at the RBC Capital Markets ... - Dec 6, 2006 American Digital Networks (press release),CollaGenex also currently sells Periostat(R), which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes MediGene's Acquisition of a License on Oracea Gives the Signal for ... - Dec 20, 2006 PharmaLive.com (press release),Periostat® and Restoraderm® are registered trademarks and IMPACS™, SansRosa™ and Oracea™ are trademarks of CollaGenex Pharmaceuticals, Inc. Novacort™ and CollaGenex Pharmaceuticals Reports Financial Results for the Third ... Nov 8, 2006 Net revenues from Periostat(R), Pandel(R), the Atrix products, contract revenues from the Primus products and grant revenue from the previously announced NIH ... -Business Wire (press release), Business news in brief Nov 4, 2006 Oracea is a formulation of doxycycline, the same active ingredient in CollaGenex's gum-disease treatment Periostat. The company, a ... -Philadelphia Inquirer, CollaGenex Pharmaceuticals Announces USPTO Allowance of Oracea ... Nov 3, 2006 CollaGenex additionally currently sells Periostat(R), which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the ... -Business Wire (press release), CollaGenex Pharmaceuticals to Present at the UBS Global Life ... Sep 19, 2006 CollaGenex also currently sells Periostat(R), which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes ... -Business Wire CollaGenex Pharmaceuticals Reports Financial Results for the ... Aug 2, 2006 ...were $3.8 million in the second quarter of 2006 compared to $6.9 million in the second quarter of 2005, reflecting reduced sales of Periostat(R) following the ... -Business Wire 2nd quarter good at 3 local biotechs Aug 3, 2006 Stewart said revenues fell after CollaGenex’s signature dental drug, Periostat, lost its patent protection and became available as a generic. ... -phillyBurbs.com Business news in brief Aug 3, 2006 ...reported sharply lower second-quarter revenue based on reduced sales of its dental treatment Periostat after lower-cost generic versions hit the market in May ... -Philadelphia Inquirer Collagenex responds to patent situation Jul 21, 2006 Oracea contains doxycycline, the same active ingredient as CollaGenex's gum disease treatment Periostat. The company began focusing ... -Philadelphia Business Journal CollaGenex Pharmaceuticals Reports Financial Results For the First ... May 3, 2006 ...$3.7 million compared to approximately $12.0 million in the first quarter of 2005, reflecting significantly reduced sales of Periostat(R) following the ... - Genetic Engineering News CollaGenex Posts Wider 1Q Loss May 3, 2006 ...said Wednesday that its first-quarter loss widened significantly as generic sales cut heavily into its Periostat gum disease treatment sales. ... - Houston Chronicle CollaGenex Pharma Q1 Loss Widens On Lower Sales Due To Generic ... May 3, 2006 ...on Wednesday reported first quarter results, posting a net loss that widened from last year on decrease in sales of the company's Periostat drug due to the ... - Trading Markets CollaGenex Pharmaceuticals Net Loss Widens In Q1 - Quick Facts May 3, 2006 ...totaled $3.7 million compared to $12 million in the prior year quarter, with the company attributing the decline in revenues to the reduced sales of Periostat. ... - Trading Markets CollaGenex Pharmaceuticals to Host First Quarter 2006 Earnings ... Apr 26, 2006 CollaGenex also currently sells Periostat, which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes that ... - Genetic Engineering News Biotechs have high hopes for ’06 May 4, 2006 The loss reflects reduced sales of the company’s Periostat dental drug since generic competition entered the market a year ago, said CEO Colin Stewart. ... - phillyBurbs.com CollaGenex Pharmaceuticals to Present at the SunTrust 35th Annual ... Apr 4, 2006 CollaGenex also currently sells Periostat, which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes that ... - Genetic Engineering News Pharma? Think small Mar 10, 2006 ...dental remedies. But in 2002 a study found that its drug for severe gum disease, Periostat, could also clear up acne. The Collagenex ... - CNNMoney.com CollaGenex Pharmaceuticals Reports Financial Results for the ... Feb 28, 2006 ...million in the fourth quarter of 2005 compared to $13.2 million in the fourth quarter of 2004, reflecting significantly reduced sales of Periostat(R) following ... - PharmaLive.com, CollaGenex Pharmaceuticals to Present at the SG Cowen 26th Annual ... Mar 1, 2006 CollaGenex also currently sells Periostat, which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes that ... - Genetic Engineering News, CollaGenex Pharmaceuticals' Announces Filing of Marketing ... Feb 27, 2006 CollaGenex also currentlysells Periostat(R), which the Company developed as the firstpharmaceutical to treat periodontal disease by inhibiting the enzymesthat ... - Finanzen.net, CollaGenex seeks UK approval for Oracea Feb 28, 2006 This loss was driven by significantly reduced sales of Periostat following the introduction of generic competition in May 2005. ... - Pharmaceutical Business Review Brand Names/Synonyms: Periostat is also known by the following brand names and/or synonymsAlti-Doxycycline; Apo-Doxy; Atridox; DOXCYCLINE ANHYDROUS; Doryx; Doxy 100; Doxy-Caps; Doxy-Lemmon; Doxychel; Doxychel Hyclate; Doxycin; Doxycycline; Doxycycline Hyclate; Doxycycline Monohydrate; Doxylin; Doxytec; Doxytetracycline; GS-3065; Jenacyclin; Monodox; Novo-Doxylin; Nu-Doxycycline; Periostat; Supracyclin; Vibra-Tabs; Vibramycin Drug Category: Periostat is categorized under the following by the FDA: Antimalarials; Anti-bacterial Agents; Tetracyclines; ATC:A01AB22; ATC:J01AA02 Dosage Forms: Tablet; Capsule; Gel; Liquid; Powder; Powder for Solution Absorption: completely absorbed after oral administration Interactions: -->Interactions for Doxycycline: Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations. Absorption of tetracycline is impaired by bismuth subsalicylate. Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline. The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity. Concurrent use of tetracycline may render oral contraceptives less effective. Drug/Laboratory Test Interactions False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test. Chemical IUPAC Name: 2-(amino-hydroxy-methylidene)-4-dimethylamino-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |